WO1997035884A8 - Improved production of antibodies through the use of combinations of antigen and antibody, test kits incorporating said antibodies, and medical uses of said antibodies - Google Patents

Improved production of antibodies through the use of combinations of antigen and antibody, test kits incorporating said antibodies, and medical uses of said antibodies

Info

Publication number
WO1997035884A8
WO1997035884A8 PCT/GB1997/000855 GB9700855W WO9735884A8 WO 1997035884 A8 WO1997035884 A8 WO 1997035884A8 GB 9700855 W GB9700855 W GB 9700855W WO 9735884 A8 WO9735884 A8 WO 9735884A8
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
antigen
antibody
test kits
combinations
Prior art date
Application number
PCT/GB1997/000855
Other languages
French (fr)
Other versions
WO1997035884A1 (en
Inventor
Arthur Randell Bradwell
Original Assignee
Binding Site Ltd
Arthur Randell Bradwell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Binding Site Ltd, Arthur Randell Bradwell filed Critical Binding Site Ltd
Priority to DE19780326T priority Critical patent/DE19780326T1/en
Priority to AU21697/97A priority patent/AU2169797A/en
Priority to GB9721432A priority patent/GB2314334A/en
Publication of WO1997035884A1 publication Critical patent/WO1997035884A1/en
Publication of WO1997035884A8 publication Critical patent/WO1997035884A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

We have been able to make high affinity and high titre antibodies by administering not only antigen to an animal, but also a relatively low dose of antibodies to that antigen. These high affinity antibodies can then be used to make better immunological diagnostic test kits, or in the preparation of therapeutic substances, or in the treatment of patients. High affinity antibodies are administered to an antibody source in order to make even higher affinity antibodies.
PCT/GB1997/000855 1996-03-27 1997-03-26 Improved production of antibodies through the use of combinations of antigen and antibody, test kits incorporating said antibodies, and medical uses of said antibodies WO1997035884A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE19780326T DE19780326T1 (en) 1996-03-27 1997-03-26 Improvements in antibody production, antibody test kits, and medical use with antibodies
AU21697/97A AU2169797A (en) 1996-03-27 1997-03-26 Improved production of antibodies through the use of antigen antibody complexes
GB9721432A GB2314334A (en) 1996-03-27 1997-03-26 Improved production of antibodies through the use of antigen antibody complexes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9606425.8A GB9606425D0 (en) 1996-03-27 1996-03-27 Improvements in and relating to the production of antibodies and test kits incorporating antibodies
GB9606425.8 1996-03-27

Publications (2)

Publication Number Publication Date
WO1997035884A1 WO1997035884A1 (en) 1997-10-02
WO1997035884A8 true WO1997035884A8 (en) 2001-04-26

Family

ID=10791102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/000855 WO1997035884A1 (en) 1996-03-27 1997-03-26 Improved production of antibodies through the use of combinations of antigen and antibody, test kits incorporating said antibodies, and medical uses of said antibodies

Country Status (4)

Country Link
AU (1) AU2169797A (en)
DE (1) DE19780326T1 (en)
GB (2) GB9606425D0 (en)
WO (1) WO1997035884A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69809754T2 (en) * 1997-07-25 2003-09-18 Altana Pharma Ag SUBSTITUTED 6-PHENYLPHENANTHRIDINE
WO2007073567A2 (en) 2005-12-22 2007-06-28 Iq Corporation Compositions and methods of modulating the immune response
WO2008142483A2 (en) * 2006-12-14 2008-11-27 Plant Research International B.V. Vaccine compositions and methods of use thereof
CN109890407A (en) * 2016-03-21 2019-06-14 大卫·B·韦纳 DNA antibody construct and its application method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0153871A3 (en) * 1984-03-01 1987-07-01 Centocor, Inc. Antibody enhancement of immunogenicity of antigen
US4879225A (en) * 1986-06-20 1989-11-07 Neorx Corporation Enhanced production of antibodies utilizing insolubilized immune complexes
US5332665A (en) * 1991-12-18 1994-07-26 The General Hospital Corporation Species specific, high affinity monoclonal antibodies

Also Published As

Publication number Publication date
WO1997035884A1 (en) 1997-10-02
GB9721432D0 (en) 1997-12-10
DE19780326T1 (en) 1998-04-23
GB2314334A (en) 1997-12-24
AU2169797A (en) 1997-10-17
GB9606425D0 (en) 1996-06-05

Similar Documents

Publication Publication Date Title
SE8902638L (en) STABILIZED PROTEIN OR PEPTIDE CONJUGATE
MXPA02000192A (en) Compositions and methods for the therapy and diagnosis of lung cancer.
EP0372501A3 (en) Synthetic antigens, method for their preparation and their use
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
EP1593393A3 (en) Anti-TNF antibodies and methotrexate in the treatment of autoimmune diseases
EP0671920A4 (en) An anti-idiotypic antibody and its use in diagnosis and in therapy in hiv-related disease.
BR0009537A (en) Compositions for treatment and diagnosis of breast cancer and methods for its use
IL97411A (en) Pharmaceutical formulations comprising hapten-modified diagnostic or therapeutic agents
EP1298203A3 (en) Diagnosis and treatment of autoimmune diseases
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
EP1767636A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
ES2138729T3 (en) DIAGNOSTIC METHODS OF PREECLAMPSIA.
PT910407E (en) METHOD AND COMPOSITION FOR MODIFYING THE CONFORMATION OF MULTI-EPITHOPIC ANTIGENS IN ORDER TO START AN IMMUNE RESPONSE
Omura et al. Early detection of autism (ASD) by a non-invasive quick measurement of markedly reduced acetylcholine & DHEA and increased β-amyloid (1-42), asbestos (Chrysotile), titanium dioxide, Al, Hg & often coexisting virus infections (CMV, HPV 16 and 18), bacterial infections etc. in the brain and corresponding safe individualized effective treatment
AU9363398A (en) Hepatitis c receptor protein cd81
DE60029953D1 (en) SPECIFIC ANTIBODIES TO HUMAN CHORIONGONADOTROPIN HORMONE AND THEIR USE IN THERAPY AND DIAGNOSIS
WO1997035884A8 (en) Improved production of antibodies through the use of combinations of antigen and antibody, test kits incorporating said antibodies, and medical uses of said antibodies
ATE407149T1 (en) DETOXIFICATION THROUGH F(AB')2 FRAGMENTS ADMINISTERED INTRAMUSCULARLY
MARTIN et al. Agammaglobulinemia: clinical staff conference at the National Institutes of Health
NZ284914A (en) use of anti-arthritogenic peptide antibodies, nonadsorbable antibiotic or benign bacteria to treat rheumatoid arthritis by enteral administration
WO2002002623A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
IL117564A (en) Pharmaceutical and diagnostic compositions containing lysine derivatives
Yates et al. Failure to demonstrate that antibody to intrinsic factor is a significant cause of vitamin B12 malabsorption in pernicious anemia.
Skårberg et al. Oxymetholone Treatment in Hypoproliferative Anaemia1: I. Frequency of Response

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

RET De translation (de og part 6b)

Ref document number: 19780326

Country of ref document: DE

Date of ref document: 19980423

WWE Wipo information: entry into national phase

Ref document number: 19780326

Country of ref document: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: CA

NENP Non-entry into the national phase in:

Ref document number: 97534149

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: GB

Free format text: 19970326 A 9721432

AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION